Current Headlines

  1. Definiens Launches Clinical Development Offering To Provide Services From Discovery To Commercialization To Maximize The Success Of Drug Programs
    8/2/2016

    Definiens, the pioneer in Tissue Phenomics solutions for diagnostic development and commercialization, recently announced the release of its Clinical Development Offering, making the company the premier provider of comprehensive tissue-based services from discovery to commercialization

  2. Simulations Plus Releases ADMET Predictor Version 8.0
    8/1/2016

    Simulations Plus, Inc., the premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, recently announced that it has released Version 8.0 of its best-in-class ADMET Predictor molecular property prediction software

  3. SciFluor Life Sciences Enters Clinical Trial Stage For Novel Treatment For Retinal Diseases
    8/1/2016

    SciFluor Life Sciences, Inc., a clinical stage biopharmaceutical company developing a portfolio of therapeutic drugs capitalizing on the transformational power of fluorine, recently announced that the Investigational New Drug (IND) Application to the Food and Drug Administration (FDA) is now in effect for SF0166 Topical Ophthalmic Solution (SF0166)

  4. Sunovion Submits New Drug Application For SUN-101/eFlow To The FDA For The Treatment Of Patients With Chronic Obstructive Pulmonary Disease (COPD)
    7/29/2016

    Sunovion Pharmaceuticals Inc. (Sunovion) recently announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for SUN-101/eFlow, an investigational treatment for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD)

  5. Frontage Laboratories, Inc. Announces Formation Of FJ Pharma, LLC, A Joint Venture With Zhejiang Jiuzhou Pharmaceutical Co, Ltd. To Provide API Development And Manufacturing Services
    7/27/2016

    Recently, Frontage Laboratories, Inc. announced that it has established a joint venture with Zhejiang Jiuzhou Pharmaceutical Co., Ltd. to provide enhanced access to high quality and economical API & intermediate development and manufacturing (CDMO) services to new US clients focused on New Chemical Entities (NCE) and vertically-integrated generic APIs that are developed through the combined efforts of Frontage and Jiuzhou

  6. Nine In 10 Life Sciences Organizations Worry About Drug Pricing Pressures – BDO Study
    7/26/2016

    The drug pricing debate continues to plague the life sciences sector, fueled by public criticism of rising costs and calls for regulatory change in the midst of the election season

  7. X-Chem And AbbVie Enter Into Multi-Target Drug Discovery Partnership
    7/26/2016

    X-Chem, Inc., a privately held biotechnology company applying its cutting-edge lead discovery capabilities to the generation of novel small molecule therapeutics, recently announced a multi-target drug discovery agreement with AbbVie

  8. Enanta Announces The U.S. Food And Drug Administration Has Approved AbbVie’s New, Once-Daily VIEKIRA XR (Dasabuvir, Ombitasvir, Paritaprevir And Ritonavir) For The Treatment Of Genotype 1 Chronic Hepatitis C Virus
    7/25/2016

    Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, recently announced that the U.S. Food and Drug Administration (FDA) has approved AbbVie’s New Drug Application (NDA) for VIEKIRA XR (dasabuvir, ombitasvir, paritaprevir and ritonavir) extended release tablets

  9. Inotek Pharmaceuticals Expands Intellectual Property Portfolio With Combination Patent
    7/22/2016

    Inotek Pharmaceuticals Corporation , a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for glaucoma and other eye diseases, recently announced that the United States Patent and Trademark Office issued a composition of matter patent for the combination of the Company’s lead product candidate, trabodenoson, with a prostaglandin analog for the treatment of intraocular pressure (IOP) in patients with glaucoma

  10. New Poll Finds 64 Percent Of Global Doctors Believe New Hepatitis C Drugs Are Worth The Cost
    7/21/2016

    In advance of World Hepatitis Day on July 28, 2016, SERMO – the leading global social network exclusively for physicians – released new poll data that queried physicians on the costs of new hepatitis C cures